ID Biomedical To Initiate Fluviral Trial For U.S. Approval By End Of January
This article was originally published in The Pink Sheet Daily
Executive Summary
ID Biomedical will begin enrolling subjects in a clinical trial evaluating its influenza vaccine Fluviral for U.S. approval before the end of January